4.4 Article

Sex-Related Longitudinal Change of Motor, Non-Motor, and Biological Features in Early Parkinson's Disease

期刊

JOURNAL OF PARKINSONS DISEASE
卷 12, 期 1, 页码 421-436

出版社

IOS PRESS
DOI: 10.3233/JPD-212892

关键词

DaTScan; motor; non-motor; Parkinson's disease; sex

资金

  1. Michael J. Fox Foundation for Parkinson's Research (MJFF)
  2. Abbvie
  3. AcureX Therapeutics
  4. Allergan
  5. Amathus Therapeutics
  6. Avid Radiopharmaceuticals
  7. Bial Biotech
  8. Biogen
  9. BioLegend
  10. Bristol-Myers Squibb
  11. Calico
  12. Celgene
  13. Denali
  14. 4D pharma pic
  15. GE Healthcare
  16. Genetech
  17. GlaxoSmithKline
  18. Golub Capital
  19. Handl Therapeutics
  20. Insitro
  21. Janssen
  22. Lilly
  23. Lundbeck
  24. Merck
  25. Meso Scale Discovery
  26. Neurocrine Biosciences
  27. Pfizer
  28. Piramal
  29. Prevail Therapeutics
  30. Roche
  31. Sanofi Genzyme
  32. Servier
  33. Takeda
  34. Teva
  35. UCB
  36. Verily
  37. Voyager therapeutics

向作者/读者索取更多资源

Men with early untreated Parkinson's disease (PD) showed greater longitudinal changes in motor and non-motor features compared to women. They also required higher dopaminergic medication dosages over time. However, there were no sex-related progression patterns observed in biological biomarkers.
Background: Investigation of sex-related motor and non-motor differences and biological markers in Parkinson's disease (PD) may improve precision medicine approach. Objective: To examine sex-related longitudinal changes in motor and non-motor features and biologic biomarkers in early PD. Methods: We compared 5-year longitudinal changes in de novo, untreated PD men and women (at baseline N= 423; 65.5% male) of the Parkinson's Progression Markers Initiative (PPMI), assessing motor and non-motor manifestations of disease; and biologic measures in cerebrospinal fluid (CSF) and dopamine transporter deficit on DaTscan (TM) uptake. Results: Men experienced greater longitudinal decline in self-reported motor (p < 0.001) and non-motor (p = 0.009) aspects of experiences of daily living, such that men had a yearly increase in MDS-UPDRS part II by a multiplicative factor of 1.27 compared to women at 0.7, while men had a yearly increase in MDS-UPDRS part I by a multiplicative factor of 0.98, compared to women at 0.67. Compared to women, men had more longitudinal progression in clinician-assessed motor features in the ON medication state (p = 0.010) and required higher dopaminergic medication dosages over time (p = 0.014). Time to reach specific disease milestones and longitudinal changes in CSF biomarkers and DaTscan TM uptake were not different by sex. Conclusion: Men showed higher self-assessed motor and non-motor burden of disease, with possible contributions from suboptimal dopaminergic therapeutic response in men. However, motor features of disease evaluated with clinician-based scales in the OFF medication state, as well as biological biomarkers do not show specific sex-related progression patterns.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据